Journal of Antimicrobial Chemotherapy (2002) 49, 403-406
© 2002 The British Society for Antimicrobial Chemotherapy
Brief report |
In vitro activity of the aerosolized agents colistin and tobramycin and five intravenous agents against Pseudomonas aeruginosa isolated from cystic fibrosis patients in southwestern Germany
Department of Microbiology and Hygiene, University of Freiburg, Freiburg, Germany
Three hundred and eighty-five mucoid and non-mucoid strains of Pseudomonas aeruginosa isolated from 192 sputa from 57 adult cystic fibrosis patients were studied. Susceptibility testing using an agar dilution technique was performed for ceftazidime, ciprofloxacin, fosfomycin, meropenem and piperacillin, and the aerosolized agents colistin and tobramycin. Meropenem, ceftazidime and piperacillin were the most potent agents (susceptibility 86.2%, 84.2% and 84%, respectively). Tobramycin and colistin susceptibility rates were lower, but in light of higher intrabronchial concentrations of these drugs a greater percentage of strains might still be clinically susceptible. Only 46.2% and 41.8% of isolates were susceptible to ciprofloxacin and fosfomycin, respectively.
* Correspondence address. UMC St Radboud, University of Nijmegen, Department of Clinical Microbiology, MMB 440, PO Box 9101, 6500 HB Nijmegen, The Netherlands. Tel: +31-24-361-9560; Fax: +31-24-3540216; E-mail: T.Schulin{at}mmb.azn.nl
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. Sun, A. Negrea, M. Rhen, and D. I. Andersson Genetic Analysis of Colistin Resistance in Salmonella enterica Serovar Typhimurium Antimicrob. Agents Chemother., June 1, 2009; 53(6): 2298 - 2305. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Aoki, K. Tateda, Y. Kikuchi, S. Kimura, C. Miyazaki, Y. Ishii, Y. Tanabe, F. Gejyo, and K. Yamaguchi Efficacy of colistin combination therapy in a mouse model of pneumonia caused by multidrug-resistant Pseudomonas aeruginosa J. Antimicrob. Chemother., March 1, 2009; 63(3): 534 - 542. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Landman, C. Georgescu, D. A. Martin, and J. Quale Polymyxins Revisited Clin. Microbiol. Rev., July 1, 2008; 21(3): 449 - 465. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. B. Bulitta, S. B. Duffull, M. Kinzig-Schippers, U. Holzgrabe, U. Stephan, G. L. Drusano, and F. Sorgel Systematic Comparison of the Population Pharmacokinetics and Pharmacodynamics of Piperacillin in Cystic Fibrosis Patients and Healthy Volunteers Antimicrob. Agents Chemother., July 1, 2007; 51(7): 2497 - 2507. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Hill, B. Rose, A. Pajkos, M. Robinson, P. Bye, S. Bell, M. Elkins, B. Thompson, C. MacLeod, S. D. Aaron, et al. Antibiotic Susceptibilities of Pseudomonas aeruginosa Isolates Derived from Patients with Cystic Fibrosis under Aerobic, Anaerobic, and Biofilm Conditions J. Clin. Microbiol., October 1, 2005; 43(10): 5085 - 5090. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. I. Morosini, M. Garcia-Castillo, E. Loza, M. Perez-Vazquez, F. Baquero, and R. Canton Breakpoints for Predicting Pseudomonas aeruginosa Susceptibility to Inhaled Tobramycin in Cystic Fibrosis Patients: Use of High-Range Etest Strips J. Clin. Microbiol., September 1, 2005; 43(9): 4480 - 4485. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Poole Aminoglycoside Resistance in Pseudomonas aeruginosa Antimicrob. Agents Chemother., February 1, 2005; 49(2): 479 - 487. [Full Text] [PDF]
|
|
|
|
|
|
M. Hogardt, S. Schmoldt, M. Gotzfried, K. Adler, and J. Heesemann Pitfalls of polymyxin antimicrobial susceptibility testing of Pseudomonas aeruginosa isolated from cystic fibrosis patients J. Antimicrob. Chemother., December 1, 2004; 54(6): 1057 - 1061. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T L Pitt, M Sparrow, M Warner, and M Stefanidou Survey of resistance of Pseudomonas aeruginosa from UK patients with cystic fibrosis to six commonly prescribed antimicrobial agents Thorax, September 1, 2003; 58(9): 794 - 796. [Abstract] [Full Text] [PDF]
|
|